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Abstract 
Objective: To study cost-effectiveness of an interleukin (IL)-17A inhibitor secukinumab, with other biologics and 
apremilast in patients with Psoriatic arthritis (PsA) from payer perspective in Finland.
Methods: In this semi-Markov model, subcutaneous (SC) secukinumab was compared with SC treatments etaner-
cept and its biosimilar, certolizumab pegol, adalimumab and its biosimilar, golimumab, ustekinumab, intravenous 
(IV) treatment infliximab, as well as oral non-biologic apremilast. Patients without prior exposure (naïve) to biologics 
and without moderate to severe psoriasis were considered for secukinumab 150 mg group. Secukinumab 300 mg 
group included naïve patients with moderate to severe psoriasis and all patients with prior biologic exposure. The PsA 
Response Criteria (PsARC) at 12-week was primary criteria for treatment response. Other clinical as well as cost related 
model inputs were derived from relevant clinical trials as well as Finnish publications. The key model outcomes were 
quality-adjusted life years and incremental cost-effectiveness ratio. An annual 3% discount rate was applied to all 
future costs and benefits. Model input variations were assessed through sensitivity analyses and alternative scenario 
analyses.
Results: For a lifetime horizon (60 years), secukinumab 150 mg dominated all branded SC biologics and apremilast 
with highest QALY of 8.01 and lowest lifetime cost of €187,776, while it was cost-effective against IV infliximab among 
biologic-naïve patients without moderate to severe psoriasis. Secukinumab 300 mg was cost-effective against all 
branded SC biologics and apremilast and dominated IV infliximab among biologic-naïve patients with moderate to 
severe psoriasis, while it was cost-effective in biologic experienced patients. With the one-way sensitivity analysis, 
PsARC response, drug acquisition cost, and health assessment questionnaire score were the most important param-
eters affecting the outcomes. Across all treatment groups, patients on secukinumab were most likely to achieve high-
est net monetary benefit than other competitors in probabilistic sensitivity analysis. With alternative scenario analysis, 
results largely remained unchanged.
Conclusions: Secukinumab is a cost-effective treatment for PsA patients from a Finnish payer’s perspective.
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Introduction
Psoriatic arthritis (PsA), a disease associated with psoria-
sis, is a chronic, multiform inflammation of joints, enthe-
ses and tendons but can also affect spine [1–4]. There 
are a lot of variations in the disease severity. Potentially, 
inflammation in PsA can lead to irreversible structural 
changes in joints and bones [5]. Incidence rates rang-
ing from 10 to 23.1 per 100,000 person-years have been 
reported in local epidemiological studies [6, 7]. Painful 
joints and entheses limit patients’ daily activities, which 
along with psoriatic skin involvement, causes substantial 
lowering of health-related quality of life [8]. In addition, 
PsA is associated with comorbidities, especially cardio-
vascular diseases, and poses significant economic burden 
over healthcare systems [9].
The European League against Rheumatism (EULAR) 
recommends the usage of conventional synthetic dis-
ease-modifying anti-rheumatic drugs (csDMARDs) as a 
first-line therapy for PsA patients. Patients with failure 
of or inadequate response to csDMARD should be con-
sidered for biologics like tumor necrosis factor Inhibitors 
(TNFi) and subsequently the interleukin inhibitors (IL 
12/23 or IL 17 inhibitors) [10, 11]. The EULAR recom-
mends the use of synthetic DMARD like apremilast in 
patients whom biologics are not appropriate. The Group 
for Research and Assessment of Psoriasis and Psori-
atic arthritis (GRAPPA) recommends to start treatment 
with csDMARDs followed by TNFi and IL inhibitors, if 
patients have inadequate response to previous therapy. 
However, in case of enthesitis, dactylitis, or nail psoria-
sis, the GRAPPA recommends TNFi and IL inhibitors 
without a trial with csDMARDs [12, 13]. In line with the 
EULAR and the GRAPPA guidelines, the Finnish current 
care guidelines also recommend starting the therapy with 
csDMARD (methotrexate) and switch to TNFi if such 
treatment is not tolerated or the response to treatment 
is inadequate. If TNFi are ineffective, switching to IL-17 
inhibitors like secukinumab is recommended [14].
Secukinumab is a first-in-class, recombinant, high-
affinity, fully human, monoclonal antibody that neutral-
izes IL-17A [4, 15]. In 2015, the European Medicines 
Agency approved secukinumab 300 mg for the treatment 
of active PsA as subcutaneous injection for patients with 
concomitant moderate to severe psoriasis or inadequate 
response to TNFi and secukinumab 150 mg for all other 
patients [16]. In multiple phase III placebo-controlled tri-
als (FUTURE trials and their extensions), secukinumab 
showed rapid, significant, and sustained efficacy across 
various clinical domains with a favorable safety pro-
file in biologic-naïve as well as in biologic-experienced 
patients (failure with up to three TNFi) [17–23]. In a 
recent network meta-analysis, secukinumab was found 
to be the most efficacious and safe treatment for PsA 
among all licensed IL-inhibitor biologics [24]. In addi-
tion, a matching-adjusted indirect comparison (MAIC) 
[25] established better efficacy of secukinumab against 
adalimumab. An ongoing head-to-head trial compar-
ing secukinumab against adalimumab (EXCEED) [26] is 
aimed to confirm results obtained from the MAIC.
This study reports the results of a cost-effectiveness 
analysis of subcutaneous (SC) secukinumab versus cur-
rently licensed biologics, biosimilars (SC certolizumab 
pegol, etanercept and its biosimilar, adalimumab and 
its biosimilar, golimumab, ustekinumab and intrave-




The cost-effectiveness analysis was conducted in adult 
PsA patients of at least 18 years of age, with active disease 
in spite of treatment with NSAIDs, csDMARDs, and/or 
TNFi. The baseline patient characteristics were derived 
from the FUTURE 2 study [17], as shown in Additional 
file 1: Table S1. Patients were classified into three groups 
based on prior exposure and response to biologics and 
psoriasis severity as, (1) biologic-naïve (no prior expo-
sure to biologics) without moderate to severe psoriasis, 
(2) biologic-naïve with moderate to severe psoriasis, 
and (3) biologic-experienced (having prior exposure to 
biologics). Biologic-naïve patients without moderate to 
severe psoriasis received 150 mg of secukinumab, while 
biologic-naïve patients with moderate to severe psoriasis 
and biologic-experienced patients received secukinumab 
300 mg. The secukinumab dosing regimen was based on 
the approved marketing authorization guidelines [16] 
and is reflective of the common prescription practice of 
rheumatologists in Finland. All patients are assumed to 
continue receiving concomitant standard of care (SoC) 
treatments. Information related to treatment regimens 
like dosing and frequencies are provided in Additional 
file 1: Table S2.
Model structure
The model, as shown in Fig. 1, had a semi-Markov struc-
ture. This model is adapted from the recently published 
cost-effectiveness study of secukinumab in Canada [27]. 
Similar structure was used in the York model [28, 29] as 
well as other economic analyses of TNFi treatments for 
PsA [30–34]. This model also allowed assessment of the 
impact of adverse events, such as malignancy and tuber-
culosis, on mortality.
Treatment initiation defined the entry point for 
patients, while a 3-month duration was considered as 
induction period. At the end of the induction period, 
patients were evaluated for treatment response using 
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the PsA response criteria (PsARC). The PsARC has been 
used extensively as a response criteria in similar analyses, 
including the York model, which allows comparability of 
this analysis with prior publications [28, 29, 31–34]. The 
PsARC as a treatment response criteria is also accepted 
by the National Institute of Health and Care Excellence 
(NICE) of the UK [35]. Based on treatment response, 
probabilities of withdrawal, serious infection includ-
ing tuberculosis, malignancy, and death, patients transi-
tioned to different health states (Fig.  1). Patients within 
the “Malignancy” state were assumed to be at a higher 
mortality risk for 5 years into that state.
Patients were able to withdraw from their initial bio-
logic and transition to a subsequent/second line biologic 
as per preference of patients and/or physicians. As data 
on the effectiveness of subsequent biologics and treat-
ment switches were limited, average values of efficacy, 
costs, treatment withdrawal rates, and adverse event 
rates were used for all biologics. Patients receiving sub-
sequent biologics were assumed to continue on this treat-
ment or move to the SoC if they dropped out.
Model inputs
Clinical inputs
The 3-month results for PsARC response, the Psoriasis 
Area and Severity Index (PASI) response, and change 
from baseline in the Health Assessment Questionnaire 
(HAQ) were the main clinical inputs used in the model, 
as shown in Table  1. Due to the lack of head-to-head 
trials in the biologic-naïve population, comparative 
effectiveness data were obtained from a network meta-
analysis (NMA) assessing PsARC and PASI outcomes 
[36], as shown in Additional file 1: Figures S1, S2.
Clinical efficacy in biologic-experienced patients is 
expected to be lower than that for biologic-naïve patients 
[37]. Hence clinical efficacy data in biologic-experienced 
patients were calculated by applying adjustment rates to 
available clinical data that compared biologic-naïve to 
biologic-experienced patients [17, 38]. Treatment with-
drawals rates are provided in Additional file 1: Table S3. 
Wherever clinical data for a comparator were missing, 
average of relevant data from other comparators within 
similar population were used as a substitute.
Cost and resource use
Four types of costs were included: drug acquisition costs, 
disease-related costs, medical support costs, and adverse 
event costs, as shown in Table  2 and Additional file  1: 
Tables S4, S5. Wherever required, these costs were infla-
tion adjusted with the latest available index and con-
verted to Euro (€).
The acquisition costs for all brand drugs were obtained 
from the Finnish medicinal products and prices database. 
Biosimilar prices for etanercept and adalimumab were 
Fig. 1 Model structure. *The efficacy parameter depends on the criteria chosen—PsARC alone (for base case analysis), PASI, or a combination of 
PsARC and PASI (for alternative scenario analysis). Tx, treatment
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considered 30% less than that for the brand price. Due to 
unavailability of Finnish PsA related costs, this category 
of costs were retrieved from the published York model in 
PsA (Table 2) [28]. A linear regression method based on 
the change from baseline in HAQ scores was employed 
to obtain the arthritis-related costs. The psoriasis-related 
costs were based on PASI response, taking into account 
both uncontrolled (PASI < 75) and controlled (PASI ≥ 75) 
disease states. Costs related to medical support and 
adverse events were based on national healthcare unit 
costs and were confirmed by expert advice (Additional 
file 1: Tables S4, S5).
Table 1 Clinical inputs at 3 months
ADA, adalimumab; APR, apremilast, CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; PsARC, Psoriatic arthritis response criteria; SEC 150, 
secukinumab 150 mg; SEC 300, secukinumab 300 mg; UST, ustekinumab
a Biologic-naive data for certolizumab pegol and ustekinumab were not available and were assumed equivalent to be average of other biologics in the NMA. Trials 
for etanercept 50 mg once weekly did not link into the network, thus data for etanercept 25 mg twice weekly were used. Data for experienced population was lacking 
and was computed by applying a reduction to mixed population. Secukinumab: 0.43% reduction, other Tumor Necrosis Factor-alpha inhibitor (TNFi): 10.1%
b Biologic-experienced data for ustekinumab were not available and were assumed equivalent to average of other biologics in the NMA. Trials for etanercept 50 mg 
once weekly did not link into the network, thus data for etanercept 25 mg twice weekly were used
c Biologic-naive data for certolizumab pegol, etanercept, golimumab and ustekinumab were not available and were assumed equivalent to the average of 
other biologics in the network meta-analysis (NMA). Secukinumab 150 mg was evaluated in biologic-naïve population without moderate to severe psoriasis and 
secukinumab 300 mg was evaluated in biologic-naïve patients with moderate to severe psoriasis
d Data for experienced population was lacking and was computed by applying a reduction to mixed population. For Sec and other Tumor Necrosis Factor-alpha 
inhibitor (TNFi): PASI 50: 1.34% and 43.08% reduction, PASI 75: 6.84% and 40.64% reduction, PASI 90: 6.67% and 41.86%
e Secukinumab 150 mg was evaluated in biologic-naïve population without moderate to severe psoriasis and secukinumab 300 mg was evaluated in biologic-naïve 
patients with moderate to severe psoriasis. For biologic-experienced patients, data were assumed equivalent to that of mixed population
# Sources: Biologic experienced, regardless of PsARC response—SEC 150 and SEC 300 from FUTURE 2 trial; CER P set equal to placebo; ETN, ADA, INF, GOL, UST, and 
APR estimated from changes in HAQ with and without PsARC response and PsARC response probabilities; biologic experienced, given PsARC response—SEC 150, SEC 
300 from FUTURE 2 trial; CER P, UST, and APR set equal to placebo; ETN, ADA, INF, and GOL from Cawson et al. [31]; biologic experienced, given no PsARC response—
SEC 150 and SEC 300 from FUTURE 2 trial; CER P, UST, and APR set equal to placebo; ETN, ADA, INF, and GOL from Cawson et al. [31]; Biologic naïve, regardless of PsARC 
response—SEC 150, SEC 300, and placebo from FUTURE 2 trial; CER P, ETN, ADA, INF, GOL, UST, and APR set equal to biologic naïve or experienced, regardless of 
PsARC response; biologic naïve, given PsARC response—SEC 150, SEC 300 from FUTURE 2 trial; CER P, ETN, ADA, INF, GOL, UST, and APR set equal to biologic naïve or 
experienced, given PsARC response; biologic naïve, given no PsARC response—SEC 150 and SEC 300 from FUTURE 2 trial; CER P, ETN, ADA, INF, GOL, UST, APR set equal 
to biologic naïve or experienced, given no PsARC response
SEC 150 SEC 300 CER P ETN ADA INF GOL UST APR
PsARC response [36] (% of patients)
Biologic Naïvea 59.82% 51.18% 73.61% 70.91% 62.84% 78.65% 79.96% 73.61% 73.61%
Biologic experiencedb N/A 82.45% 67.89% 68.38% 51.72% 67.73% 59.90% 60.87% 46.04%
PASI response [36] (% of patients)
PASI score Biologic Naïvec
PASI < 50 24.70% 21.94% 26.30% 26.30% 30.00% 13.35% 39.43% 26.30% 26.30%
PASI 50-74 22.73% 21.92% 23.12% 23.12% 23.79% 17.84% 24.31% 23.12% 23.12%
PASI 75-89 23.00% 23.39% 22.71% 22.71% 21.90% 23.22% 19.23% 22.71% 22.71%
PASI 90-99 29.57% 32.76% 27.87% 27.87% 24.31% 45.58% 17.03% 27.87% 27.87%
PASI 100 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Biologic experiencedd
PASI < 50 N/A 19.63% 74.10% 74.48% 58.98% 48.84% 63.39% 58.00% 80.40%
PASI 50-74 N/A 16.87% 11.80% 11.72% 12.47% 8.83% 12.86% 12.31% 10.11%
PASI 75-89 N/A 23.01% 8.91% 8.76% 13.96% 14.30% 12.64% 14.17% 6.47%
PASI 90-99 N/A 40.49% 5.20% 5.04% 14.60% 28.03% 10.82% 15.52% 3.01%
PASI 100 N/A 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Change in  HAQe#
Biologic Naïve
Regardless of PsARC response − 0.4780 − 0.5780 − 0.2410 − 0.5259 − 0.3579 − 0.5578 − 0.3629 − 0.1988 − 0.2363
Given PsARC response − 0.5430 − 0.6880 − 0.3950 − 0.6400 − 0.4900 − 0.6600 − 0.4400 − 0.3950 − 0.3950
Given no PsARC response − 0.2310 − 0.2500 0.0000 − 0.2000 − 0.1400 − 0.2000 − 0.0600 0.0000 0.0000
Biologic experiencede
Regardless of PsARC response N/A − 0.5360 − 0.2410 − 0.5259 − 0.3579 − 0.5578 − 0.3629 − 0.1988 − 0.2363
Given PsARC response N/A − 0.5360 − 0.3950 − 0.6400 − 0.4900 − 0.6600 − 0.4400 − 0.3950 − 0.3950
Given no PsARC response N/A − 0.3270 0.0000 − 0.2000 − 0.1400 − 0.2000 − 0.0600 0.0000 0.0000
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The indirect costs were not included in the base case 
analysis. However, alternative scenarios were run by 
incorporating indirect costs in a form of productiv-
ity loss due to PsA. Loss of productivity was calculated 
based on Health Assessment Questionnaire Disability 
Index (HAQ-DI) scores. Based on the HAQ-DI scores, 
patients were distributed into six categories, and unem-
ployment rate was assigned to each category: rate 24% 
for HAQ-DI score < 0.6, rate 41% for score ≥ 0.6–1.1, 
rate 45% for score ≥ 1.1–1.6, rate 44% for score ≥ 1.6–
2.1, rate 68% for score ≥ 2.1–2.6, rate 87% for 
rate ≥ 2.6–3.0 [39]. The unemployment rates were mul-
tiplied with the cost of productivity derived from the 
Finnish National Institute of Health and Welfare to 
obtain productivity loss due to unemployment for each 
category (Additional file 1: Table S5).
Other inputs
In the base case analysis, utility values from the FUTURE 
2 trial [17] were used for each cycle, which were calcu-
lated by converting EQ-5D scores with Dolan [40] algo-
rithm using a representative UK population. Utility 
values for scenario analysis were taken from the York 
model, [28] which were calculated by using HAQ and 
PASI scores and applying linear regression method. The 
values are shown in Additional file  1: Table  S6. Three 
mortality risks were included in the analysis as shown in 
Additional file 1: Table S7. Finnish age-specific life tables 
were used to take into account the all-cause mortal-
ity. The disease-specific mortality risk was based on risk 
values used in the York model [28]. The adverse event-
related mortality risk is based on the evidence showing 
similar mortality risk for PsA patients to that of the gen-
eral population [41].
Base case analysis
The base case analysis compared cost-effectiveness of 
secukinumab 150  mg and 300  mg with that of licensed 
biologics, their biosimilars, and apremilast from a Finn-
ish payer’s perspective. Using quality-adjusted life 
years (QALYs) as the primary effectiveness outcome, 
secukinumab’s dominance over other comparators was 
assessed. Dominance was defined as having higher QALY 
at lower cost over a comparator. In case secukinumab 
was non-dominant, the incremental cost-effectiveness 
ratio (ICER) was reported. A commonly referred willing-
ness-to-pay (WTP) threshold of €30,000/QALY was used 
for assessing the cost-effectiveness, as there is no man-
dated WTP threshold in Finland. Annual discount rates 
of 3% were applied for both future costs and outcomes. 
The analysis was done for a lifetime horizon of 60 years.
Sensitivity analyses
Three sensitivity analyses assessed the impact of vari-
ations of input parameters on the base case results. In 
one-way deterministic analysis, input parameters likely 
to have the greatest impact on the results (e.g., PsARC 
response rate, HAQ change, and utility weights) were 
varied one at a time.
The scenario analyses allowed changing model struc-
tures and assumptions to ascertain their impact on base 
case results. Some of these scenarios included time hori-
zons of 5 and 10 years, discount rates of 0% and 5%, alter-
native utility values, addition of indirect costs, inclusion 
of disutilities, and HAQ score retaining after treatment 
withdrawal.
Table 2 Costs inputs
ADA, adalimumab; APR, apremilast; CER P, certolizumab pegol; ETN, etanercept; 
GOL, golimumab; HAQ, Health Assessment Questionnaire; INF, infliximab; 
LEF, leflunomide; MTX, methotrexate; PASI, Psoriasis Area Severity Index; SEC, 
secukinumab; SUL, sulfasalazine; UST, ustekinumab
Source: Costs from the York model (Rodgers et al., [28]) who extracted costs from 
the following sources. Cost for a 1-point change in HAQ obtained from Kobelt 
et al. [49]. Cost for uncontrolled psoriasis obtained from Department of Health 
[50]. Cost for controlled psoriasis obtained from Hartman et al. [51]
a Finnish medicinal products and prices database [accessed on-line 2.1.2018]. 
All prices exclude value added tax. Retail price for SC products, and wholesale 
price for IV products is applied according to local guidelines. Infliximab price 
is weighed with market share. A cost of €382 (2016 value) is added for each IV 
administration [48] Biosimilar pricing for etanercept and adalimumab assumed 
to be 30% less than brand; they were not available in the market at the time of 
analyses, and thus only used for sensitivity analysis
Drug/input Cost (€) Unit
Drug acquisition costsa
SEC 150 mg 584.43 Per dose
SEC 300 mg 1168.86 Per dose
CER P 200 mg 483.07 Per prefilled syringe
ETN 50 mg 260.04 Per prefilled syringe
ADA 40 mg 527.41 Per prefilled syringe
INF 100 mg 436.06 Per vial
GOL 50 mg 1086.93 Per prefilled syringe
UST 45/90 mg 3124.96 Per prefilled syringe
APR 10–30 mg 418.52 Per 14 day pack
APR 30 mg 14.93 Per tablet
ETN biosimilar 50 mg 182.02 Per prefilled syringe
ADA biosimilar 40 mg 369.19 Per prefilled syringe
MTX 7.5 mg 0.51 Per dose
Disease-related costs
Intercept 297.89 Per 3 months
Cost per HAQ change 131.61 Per 1-unit change per 
3-months
Health states
Uncontrolled psoriasis (PASI < 75) 253.14 Per 3 months
Controlled psoriasis (PASI ≥ 75) 20.46 Per 3 months
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In probabilistic sensitivity analysis, certain distribu-
tions were assigned for input parameters to assess the 
impact of sampling uncertainty. Input parameters like 
response rate, costs, and utility weights were varied in 
this analysis. The net monetary benefit (NMB) statistics 
was used for this analysis, as it allows simultaneous com-
parisons of multiple comparators [42]. NMB represents 
monetary value of a comparator at a defined WTP.
Results
Base case results
The QALYs, cost, and ICER related results for base case 
are provided in Table 3. For biologic-naïve patients with-
out moderate to severe psoriasis, secukinumab 150  mg 
dominated all SC administered biologics, biosimilars, as 
well as the oral apremilast by achieving highest QALY 
(8.01) at lowest life-time cost (€187,776). The IV admin-
istered infliximab had slightly higher QALY (+ 0.06), but 
at an ICER of €680,427/QALY gained vs secukinumab. 
Hence infliximab was not considered as a cost-effective 
option compared with secukinumab 150 mg.
In biologic-naïve patients with moderate to severe pso-
riasis, secukinumab 300 mg achieved the highest QALY 
(7.78) against all biologics, biosimilars, and oral apremi-
last at the life-time cost of €231,477. Based on the WTP 
of €30,000/QALY, secukinumab 300  mg was cost-effec-
tive against all SC branded biologics but not against the 
SC biosimilars of etanercept and adalimumab. Secuki-
numab 300 mg was cost-effective against oral apremilast, 
while it dominated the IV infliximab with higher QALYs 
and lower costs.
Biologic-experienced patients on secukinumab 300 mg 
achieved highest QALY (8.75) against all biologics, bio-
similars, and oral apremilast at the life-time cost of 
€256,019. Secukinumab was cost-effective against all 
branded biologics and oral apremilast. When compared 
to etanercept and adalimumab biosimilars, the ICER was 
above the €30,000 WTP threshold.
Multiple comparison across comparators was con-
ducted through cost-effectiveness frontier, as seen in 
Fig.  2. In the biologic naïve population without moder-
ate to severe psoriasis, secukinumab 150  mg, etaner-
cept biosimilar, adalimumab biosimilar, and infliximab 
had the highest cost-effectiveness. In biologic naïve 
patients with moderate to severe psoriasis, etanercept 
biosimilar and secukinumab 300 mg were the most cost-
effective options. Lastly, in biologic experienced popu-
lation etanercept biosimilar, adalimumab biosimilar, 
and secukinumab 300  mg were the most cost-effective 
options. Overall, secukinumab was the only branded bio-
logic to be cost-effective in multiple comparison across 
all patient groups.
Sensitivity analyses
In the one-way sensitivity analysis, across all patient 
groups, PsARC response at 3-month, drug acquisition 
cost, and HAQ without PsARC response were the most 
important input parameters that affected the expected 
net monetary benefits. Detailed results are shown in tor-
nado diagrams in Additional file 1: Figures S3–S5.
Complete description of alternative inputs for differ-
ent scenarios and their impact on the base case results 
Table 3 Costs, QALYs and ICER values for all analyzed populations
ADA, adalimumab; APR, apremilast; BS, biosimilar; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; IV, Intra Venous; PsARC, Psoriatic 
arthritis response criteria; QALY, quality-adjusted life-year; SEC 150, secukinumab 150 mg; SEC 300, secukinumab 300 mg; SC, subcutaneous; SoC, standard of care; 
UST, ustekinumab
a The ICER of Sec 150 mg vs. INF
Incremental SC IV Oral
SEC ETN ETN BS ADA ADA BS CER P GOL UST INF APR
SEC 150 mg versus comparators in Biologic Naïve population without moderate to severe psoriasis)
Total cost (€) 187,776 208,375 186,581 207,568 186,543 204,899 197,566 214,749 230,650 192,319
QALYs 8.01 7.67 7.67 7.47 7.47 7.34 7.15 7.54 8.07 7.13
ICER (€/QALY) – Dominates 3514 Dominates 2283 Dominates Dominates Dominates 680,427a Dominates
SEC 300 mg versus comparators in Naïve PsA with moderate to severe psoriasis population
Total cost (€) 231,477 214,225 192,431 213,555 192,530 210,480 203,855 220,313 235,354 198,422
QALYs 7.78 7.12 7.12 6.9 6.9 6.78 6.57 6.98 7.54 6.57
ICER (€/QALY) – 25,872 49,365 20,342 37,251 20,955 22,819 13,941 Dominates 27,233
SEC 300 mg versus comparators in experienced population
Total cost (€) 256,019 € 215,772 194,424 210,940 191,975 211,230 201,556 217,194 231,440 196,293
QALYs 8.75 7.35 7.35 7.05 7.05 7.00 6.75 7.12 7.61 6.68
ICER (€/QALY) – 28,742 40,546 26,609 34,959 25,623 27,293 23,832 21,631 28,939
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are shown in Additional file 1: Table S8. In majority of 
alternative scenarios, the results were similar to that 
from the base case, suggesting the robustness of our 
analysis.
In the probabilistic sensitivity analysis, patients on 
secukinumab were most likely to achieve highest QALY 
compared to all other comparators. Probability of achiev-
ing highest NMB was more than 70% in biologic-naïve 
patients on secukinumab 150  mg at WTP of €30,000 
(Additional file 1: Table S9). In patients receiving secuki-
numab 300 mg, irrespective of prior biologic experience, 
probability of achieving highest NMB was over 83% at 
WTP of €30,000 (Additional file  1: Table  S9). The cost-
effectiveness acceptability curves indicated that secuki-
numab had the highest probability of being cost-effective 
vs other comparators at the WTP threshold ranging from 
€20,000 to €100,000 across the three patient populations 
(Fig. 3). The details of the probabilistic sensitivity analysis 
are presented in Additional file 1: Table S9.
Discussion
In this analysis, secukinumab proved to be either the 
dominant or cost-effective treatment option against all 
biologics and the oral apremilast among PsA patients. 
These results hold true in all analyzed patient popula-
tions, irrespective of their prior exposure to biologics.
With highest QALYs and lowest cost, secukinumab 
150  mg provides the best economic value amongst bio-
logic-naïve patients without moderate to severe psoriasis. 
Even with slightly higher QALYs (0.06), the choice of inf-
liximab is still not justified due to its significantly higher 
costs (> €42,000) than secukinumab. Considering the 
ease of administration and lower costs, SC secukinumab 
may be more desirable by both patients and physicians 
over the IV infliximab [43, 44].
Secukinumab 300  mg was also cost-effective in both 
biologic-naïve (with moderate to severe psoriasis) and 
experienced patients compared with all branded SC 
biologics and oral apremilast at WTP €30,000/QALY, 
Fig. 2 Cost effective frontier: a secukinumab 150 mg, b secukinumab 300 mg, c secukinumab 300 mg. ADA, adalimumab; APR, apremilast; BS, 
biosimilar; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; PsA, Psoriatic arthritis; QALYs, quality adjusted life years; SEC, 
secukinumab; UST, ustekinumab
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while it dominated the IV infliximab in these subpopula-
tions with lower costs and higher QALYs. Secukinumab 
300 mg achieved higher QALYs than biosimilars of adali-
mumab (biologic-naïve: + 0.88; biologic experienced: 
+ 1.70) and etanercept (biologic-naïve: + 0.66; biologic 
experienced: + 1.40). However, ICER for secukinumab 
compared to these biosimilars were above €30,000/QALY 
gained.
This being a first comprehensive economic analysis of 
secukinumab against multiple treatment choices in Fin-
land, will help both payers and physicians in their deci-
sion making. So far, most of such analyses have focused 
on the UK perspective and have largely compared etaner-
cept to various biologics [28–34]. This analysis com-
pares secukinumab, a newer biologic with a new mode of 
action, to the current standard biologic TNFi, TNFi bio-
similars, as well as oral apremilast.
The strength of this analysis can be attributed to vari-
ous factors. The clinical inputs in the model were taken 
from an NMA, consisting of 6021 patients in 20 RCTs. 
Patients in this NMA were a mix of those with and 
without prior biologic exposure, which makes clinical 
inputs in this model reliable. Inclusion of costs like hos-
pitalization costs and diagnosis costs, in addition to drug 
acquisition and adverse event costs, allows comprehen-
sive representation of direct economic burden of PsA. 
The model results are robustly tested through both prob-
abilistic and deterministic sensitivity analyses, while the 
model structure and methodology are similar to those 
used in a model for Canadian healthcare system [27].
This model-based analysis naturally has some limi-
tations. One limitation of the analysis lies in the use of 
efficacy data from the NMA that used short-term study 
period of 12–16 weeks to project life-time efficacy. How-
ever, use of short term data may have underestimated 
the long-term efficacy of secukinumab over its compara-
tors. For example, in one of the MAIC analysis, long term 
efficacy of adalimumab [25, 45], etanercept [46], and 
infliximab [47] were compared to that of secukinumab. 
In these studies covering a period of more than 3 years, 
secukinumab maintained its significantly higher efficacy 
over the TNFi. Another limitation is the assumption that 
Fig. 3 Probability of achieving highest NMB: Cost-effectiveness Acceptability Curve with a secukinumab 150 mg, b secukinumab 300 mg, c 
secukinumab 300 mg. ADA, adalimumab; APR, apremilast; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; SEC, 
secukinumab; UST, ustekinumab
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efficacy for the biologics with missing data was equal 
to the average of other biologics. Finally, indirect costs 
were not included in the base case analysis as the model 
is from a payer’s perspective. Nevertheless, inclusion of 
indirect costs did not affect the model results, as explored 
in the alternative scenario analysis.
Conclusion
Patients on secukinumab achieved highest gains in the 
quality adjusted life-years against all comparators regard-
less of secukinumab dose, severity of concomitant pso-
riasis, or prior exposure to biologics. Secukinumab was 
either cost-saving or cost-effective when compared with 
the currently used alternative treatment options for the 
treatment of active Psoriatic arthritis from a payer’s per-
spective in Finland.
Additional file
Additional file 1. Sensitivity analyses and model input parameters
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